Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans
Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Brand Name : FlecIH-103
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Brand Name : Inrhythm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2022
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program
Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Brand Name : InRhythm
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2021
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Brand Name : FlecIH
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Brand Name : InRhythm
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide
Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?